Myelodysplastic Syndromes (MDS)

Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study

Original Publication Date

May 3, 2023

Article Source

External Web Content

Key Points In MDS, health-related quality of life (HRQoL) was worse for vulnerable participants and those with worse prognosis. Lower-risk MDS was associated with better HRQoL, but this relationship was lost among the vulnerable. Health-related quality of life (HRQoL) and…

What is the IPSS-M for MDS?

Thumbnail for video Watch Now

Topic(s)

Myelodysplastic Syndromes (MDS)

Presenter(s)

Gail J. Roboz, M.D.

In this webinar, Dr. Gail Roboz discusses the Molecular International Prognostic Scoring System (IPSS-M) which is a newly developed risk stratification model for myelodysplastic syndromes (MDS) that expands on the original IPSS-R by including data on somatic oncogenic mutations…

Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study

Read more about Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study

Recurrent mutations in TP53, RAS pathway and JAK2 genes were shown to be highly prognostic of allogeneic hematopoietic cell transplant (alloHCT) outcomes in myelodysplastic syndromes

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

Read more about Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Read more about Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Two articles in this week’s issue focus on the use of ipilimumab and decitabine decitabine: It works by reducing the amount of methylation in the body.

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

Read more about Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia

Read more about Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome

Read more about Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes

Read more about Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes

Background: Older patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-ti

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes

Read more about Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes

Background: Older patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-ti

Subscribe to Myelodysplastic Syndromes (MDS)

NFL Player Teams Up with AAMDSIF

Myelodysplastic Syndromes (MDS)

Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study

What is the IPSS-M for MDS?

Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes

Website Feedback